Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)

Tong Shen, Ye-Hong Kuang, Charles R. Ashby et al. · 2009

Read Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10) by Tong Shen, Ye-Hong Kuang, Charles R. Ashby et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0007520.txt.

Description

Tong Shen and colleagues published a study in PLOS ONE in 2009 on how cancer cells resist chemotherapy. One major trick is pumping drugs back out of the cell. Transport proteins of the ABC family do that pumping, lowering the drug level inside. One such pump is MRP7, also called ABCC10. The team tested two existing leukemia drugs, imatinib and nilotinib, against that pump.

Both drugs inhibited MRP7's efflux activity. With the pump jammed, cancer cells lost their multidrug resistance. The chemotherapy could build up inside and work again. Repurposing existing medicines this way is attractive because their safety is already known. The study suggests certain leukemia drugs could double as resistance breakers for other cancers. That is a practical shortcut in a field that moves slowly.

Catalog record

CREATORTong Shen, Ye-Hong Kuang, Charles R. Ashby et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE40 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007520

Browse the full library · About the Tower of Babel